Not Signed In - Nastech Initiates Dose Ranging Study Of PYY(3-36) Nasal Spray For Obesity
Tue, 15 Aug 2006 07:00 AM EST
... NastechPharmaceutical Company Inc. (Nasdaq: NSTK) announced today the initiationof a dose ranging study designed to evaluate the pharmacokineticparameters, appetite, food intake and safety of various doses of Nastech'sproprietary PYY(3-36) nasal spray in obese subjects. [click link for full article] ...
Related Topics
- Calcitonin Salmon Nasal Spray
- Mometasone Nasal Spray
- Sumatriptan Nasal Spray
- Zolmitriptan Nasal Spray
- Nicotine nasal spray
- Azelastine Nasal Spray
- Triamcinolone Nasal Inhalation
- Obesity
- Fluticasone Nasal Inhalation
- Beclomethasone Nasal Inhalation
- Cromolyn Nasal Spray
- Budesonide Nasal Inhaler
- Butorphanol Nasal Spray
- Xylometazoline Nasal
- Ipratropium Nasal
- Desmopressin Nose Spray
- Obesity and Overweight
- Overweight and Obesity
- Flunisolide Nasal Inhalation
- Triamcinolone Nasal Spray
email this page
print this page
bookmark this page
feedback on this page
